A phase II trial of high dose cytarabine and fludarabine without anthracycline for patients with core binding factor acute myeloid leukaemia, measuring efficacy, safety and monitoring minimal residual disease

DOI number 10.58109/q491-jt40
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

Paula Marlton (Princess Alexandra Hospital)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 53 patients
  • Rare and targetted patient population
  • Dataset includes demographic data, diagnostic, treatment data, outcome data
  • Not published
  • Data regarding safety and efficacy of medication used in AML
  • Patients who underwent BMT censored from this study

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)


ANZCTR Reference ACTRN12605000152628
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au